CURE vs SPY
Direxion Daily Healthcare Bull 3X ETF vs State Street SPDR S&P 500 ETF Trust
Quick Verdict
SPY has a lower expense ratio. CURE delivered stronger 1-year returns. SPY offers more diversification with 503 holdings.
Side-by-Side Comparison
| Metric | CURE | SPY | Winner |
|---|---|---|---|
| Expense Ratio | 0.94% | 0.09% | |
| AUM | $181M | $789.1B | |
| Dividend Yield | 1.12% | 1.01% | |
| Holdings | 67 | 505 | |
| YTD Return | +15.97% | +13.39% | |
| 1Y Return | +89.64% | +22.52% | |
| 3Y Return (annualized) | +8.52% | +21.36% | |
| 5Y Return (annualized) | +2.88% | +13.19% | |
| Volatility (annualized) | 41.9% | 15.3% | |
| Max Drawdown | -69.2% | -56.5% | |
| Fund Family | Direxion Shares ETF Trust | State Street Investment Management | |
| Category | Alternative | Equity | |
| Inception | Jun 15, 2011 | Jan 22, 1993 |
CURE vs SPY Performance
Direxion Daily Healthcare Bull 3X ETF (CURE) is a ETF from Direxion Shares ETF Trust and State Street SPDR S&P 500 ETF Trust (SPY) is a ETF from State Street Investment Management. Over the past year CURE returned +89.64% while SPY returned +22.52%. Year to date, CURE is up 15.97% versus a gain of 13.39% for SPY.
Over three years, CURE compounded at +8.52% per year against +21.36% for SPY; over five years the annualized figures are +2.88% and +13.19% respectively. Across the full 15-year window we track, CURE has the edge at +24.48% annualized vs +8.84%. Past performance does not guarantee future results.
Risk: Volatility and Drawdowns
CURE has been the more volatile fund, with annualized monthly volatility of 41.9% compared with 15.3% for SPY. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -69.2% for CURE and -56.5% for SPY. Drawdown depth is worth weighing if you expect to sell during market stress rather than ride it out.
The two funds' monthly returns correlate at 0.73. They usually move together, but the gap leaves some room for diversification.
Fees and Cost Over Time
CURE charges 0.94% per year while SPY charges 0.09%. On a $10,000 position that is $94 vs $9 annually, a gap of $85 per year that compounds over a long holding period. On income, CURE currently yields 1.12% against 1.01% for SPY.
Holdings Overlap
CURE and SPY share 59 holdings out of 506 unique holdings combined, representing a 9.0% weight overlap.
Moderate overlap means holding both could provide meaningful diversification benefits.
Frequently Asked Questions
Which is cheaper, CURE or SPY?
CURE has an expense ratio of 0.94% while SPY charges 0.09%. SPY is the cheaper option. On a $10,000 investment, that is $85 per year of difference.
Which performed better, CURE or SPY?
Over the past year CURE returned +89.64% vs +22.52% for SPY, so CURE leads on 1-year performance. Over the longest common window we track (15 years), CURE annualized +24.48% vs +8.84% for SPY. Past performance does not guarantee future results.
Which is riskier, CURE or SPY?
CURE has been the more volatile fund at 41.9% annualized versus 15.3% for SPY. Worst drawdown: CURE -69.2% vs SPY -56.5%.
Should I hold both CURE and SPY?
CURE and SPY have a monthly-return correlation of 0.73, so combining them can provide real diversification depending on your allocation goals.
What is the holdings overlap between CURE and SPY?
CURE and SPY share 59 common holdings with a 9.0% weight overlap. Combined, they hold 506 unique securities.
Which pays a higher dividend, CURE or SPY?
CURE yields 1.12% while SPY yields 1.01%, so CURE currently pays the higher dividend yield.
Popular ETF Comparisons
Get Full ETF Analytics
Access complete holdings data, overlap analysis, screener tools, and more with FundXLS.